AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05123326 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic tests for Thrombophilia
Description: Tests for JAK2 mutation, CAL R mutation and Factor V Leiden mutation will be done.
Study NCT05123326 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA tests/ Functional assays
Description: Antithrombin III, Protein C, Protein S, Factor VIII, VWF using commercial assays
Study NCT04580251 — intervention group
Intervention type: PROCEDURE
Intervention: Targeted axillary dissection
Description: The surgical treatment procedure of targeted axillary dissection performed in patients in whom the pathological lymph nodes have been marked using the examined and compared markers (magnetic marker Magseed, iodine seed 125I, carbon suspension)
Study NCT05053191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partnership, Assessment, Care and Transition training intervention
Description: Partnership, Assessment, Care and Transition to psychosocial resources. Nurses who participate in PACT will receive 8 hours of training in a single, full-day workshop. We will train nurses in clusters of 10-12 nurses at one time, which will allow for cross-coverage with minimal disruption to workflow, and provide a more intimate, small-group learning environment.
Study NCT04409912 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus coated balloon
Description: Sirolimus has a high transfer rate to the vessel wall and effectively inhibit neointimal hyperplasia in the porcine coronary model. In coronary artery interventions, preliminary clinical studies using sirolimus coated balloon have shown excellent procedural and 6 month patency. The effectiveness of sirolimus coated balloon in patients with dialysis access dysfunction has been shown in a small pilot study in the salvage of thrombosed arteriovenous graft.~When compared to Paclitaxel, sirolimus is cytostatic in its mode of action with a high margin of safety.
Study NCT04409912 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Plain balloon
Description: Plain balloon angioplasty is the current standard therapy to treat stenosis in dialysis access. However, the mid and long term patency of plain balloon angioplasty in patients with end stage renal disease is poor. The average primary patency is around 40 to 50 percent at 1 year and multiple repeated angioplasty is required to maintain the patency of the vascular access.
Study NCT06422650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella Sativa capsule 500mg
Description: Nigella Sativa capsule 500mg twice daily for 8 weeks
Study NCT05739188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-GPRC5D CAR-T cells infusion
Description: This is a3+3dose escalation study, in which three dose groups are set three different dose levels of CAR-T cells:~Dose level one: 3.0×10\^6 /kg±20%; Dose level two:6.0×10\^6 /kg±20%; Dose level three:1.0×10\^7 /kg±20%.
Study NCT04882709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Receiver-in-canal hearing aid 1 default
Description: A receiver-in-canal hearing aid developed by the Study Sponsor used with the default settings as specified in the Study Sponsor's fitting software.
Study NCT04882709 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Receiver-in-canal hearing aid 2
Description: A receiver-in-canal hearing aid developed by another hearing aid manufacturer used with the default settings as specified in the manufacturer's fitting software.
Study NCT04882709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver-in-canal hearing aid 1 strategy 1
Description: A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.
Study NCT04882709 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Receiver-in-canal hearing aid 1 strategy 2
Description: A receiver-in-canal hearing aid developed by the Study Sponsor used with a modified compression strategy that is expected to improve the sound quality.
Study NCT06422650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo identical to astaxanthin
Study NCT05759845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate 25Mg Tab
Description: topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks
Study NCT05759845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline 25 Mg Oral Tablet
Description: Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
Study NCT05759845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topiramate 25mg plus amitriptyline 25mg
Description: topiramate 25mg daily for 7 days followed by 25mg twice daily for 11 weeks with Amitriptyline 10 Mg Oral Tablet daily for 7 days followed by 25mg daily for 11 weeks
Study NCT06451718 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracorneal implantation
Description: Intracorneal implantation of the nitinol investigational device
Study NCT03513042 — intervention group
Intervention type: RADIATION
Intervention: Intensity Modulated Proton Therapy (IMPT) +/- Chemotherapy
Description: Standard of care:~* IMPT (conventional fractionation \[35x1,55/2Gy, 5 fractions/week\] or accelerated fractionation \[35x1,55/2Gy, 6 fractions/week\])~* with or without concurrent cisplatin (100 mg/m2 \[d1, d22 and d43\] or 40 mg/m2 weekly) or cetuximab (weekly 400 mg/m2 in 2h followed by 250 mg/m2 in 1h)
Study NCT04270643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: ATC code A11CC05 (cholecalciferol)
Study NCT04270643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ethyl oleate
Study NCT05101720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Axillary Venous Access
Description: Direct visualization of axillary vein will be obtained with ultrasound sterile linear probe.
Study NCT05101720 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy-Guided Axillary Venous Access
Description: Fluoroscopic landmarks will be used and axillary venous puncture will be performed without ultrasound
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg, IV, on day1 of Q3W, 2 cycle
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2, IV, day 1 of Q3W
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2, IV, day 1 of Q3W
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin AUC (area under curve) 2, IV, day 1-3 of Q3W
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nedaplatin
Description: Nedaplatin 80-100 mg/m\^2, IV, day 2-4 of Q3W
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nedaplatin
Description: Nedaplatin 80-100 mg/m\^2, IV, day 2-4 of Q3W
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel 260 mg/m\^2, IV, day 1 of Q3W
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab paclitaxel
Description: Nab paclitaxel 260 mg/m\^2, IV, day 1 of Q3W
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2, IV, day 1 of Q3W
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2, IV, day 1 of Q3W
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal paclitaxel
Description: Liposomal paclitaxel 135-175 mg/m\^2, IV, day 1 of Q3W
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal paclitaxel
Description: Liposomal paclitaxel 135-175 mg/m\^2, IV, day 1 of Q3W
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W
Study NCT06102395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluorouracil
Description: Fluorouracil 750 mg/m\^2, IV, day 1-5 of Q3W
Study NCT05154396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Patients with her2-positive early breast cancer were treated with a dose escalation regimen of neratinib or a routine dose of neratinib combined with loperamide
Study NCT04186585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP-C2
Description: Oral daily intake
Study NCT05242289 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CytoSorb
Description: Medical device used hemoperfusion and cytokine adsorption in conjunction with lung transplantation.
Study NCT06235502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based cycle-exercise for COPD patients
Description: Patients will cycle in their own home using a pedal exerciser connected to the 4M-video app
Study NCT06235502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Exercise at Fitness Center, home based exercise according to a programme
Study NCT05130593 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Nutrasorb bar
Description: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings
Study NCT05375422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SARAH
Description: Set of exercises with components of muscle strengthening, range of motion gain and home exercises.
Study NCT05375422 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Information related to joint protection, use of splints, assistive devices and other general advice, as needed.
Study NCT05375422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Information related to joint protection, use of splints, assistive devices and other general advice, as needed.
Study NCT05188989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 2.5mg group
Description: TPN171H 2.5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
Study NCT05188989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 5mg group
Description: TPN171H 5mg taken orally on demand 0.5-4 hour prior to sexual intercourse
Study NCT05188989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN171H 10mg group
Description: TPN171H 10mg taken orally on demand 0.5-4 hour prior to sexual intercourse
Study NCT05188989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: Placebo taken orally on demand 0.5-4 hour prior to sexual intercourse
Study NCT06255795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chidamide, anti-PD1 antibody, and pegaspargase
Description: 6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, anti-PD1 antibody 200mg intravenously on day 2, chidamide 30mg biw orally, every 21 days.
Study NCT06255795 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DDGP
Description: 6 cycles of pegaspargase 2500IU/m2 intramuscularly on day1, cisplatin 20mg/m2 intravenously on days 1 through 4, dexamethasone 15mg/m2 intravenously on days 1 through 5, gemcitabine 800mg/m2 on day 1 and day 8, every 21 days.
Study NCT05154396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neratinib
Description: Patients with her2-positive early breast cancer were treated with a dose escalation regimen of neratinib or a routine dose of neratinib combined with loperamide
Study NCT05537155 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buccal acupuncture in addition to routine care
Description: Acupuncture will be performed at a depth of 10 mm, with the needle retaining for 20 min, in addition to routine care. Bilateral acupoints include Tou, Shangjing, Jing, Bei, and Sanjiao. Unilateral acupoints is related to surgical sites and include Kuan in hip joint replacement surgery and Xi in knee joint replacement surgery. Patients with agitation will be treated first until agitation is controlled before acupuncture is performed.
Study NCT05537155 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routing care includes the following: (1) remove the precipitating cause and treat the primary disease; and (2) supportive care, including reorientation and cognitive stimulation, sleep enhancement, early mobility and exercise, vision and hearing optimization, family engagement and empowerment, and early oral intake and nutrition.
Study NCT06360744 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Johnson & Johnson
Description: Vaccination with the Johnson \& Johnson vaccine which is NOT part of the Danish National Government programme
Study NCT06390917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PVA recognition function
Description: Ventilator with the function of identify and judge PVAs
Study NCT04863924 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid Biopsy
Description: All patients will have a liquid biopsy with ctDNA molecular profiling
Study NCT05432674 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Digital Fall Prevention
Description: Exercises delivered through a tablet and remote motivational calls
Study NCT06257797 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Skin prick test
Description: Fenugreek wiil be tested by mixing fenugreek seed powder with saline at non-irritating doses and it will be performed by prick-by-prick test. The skin tests will be read 20 minutes after the execution.
Study NCT04897945 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Shared decision-making for diabetes prevention
Description: Pharmacists and/or nurses will engage patients with history of gestational diabetes mellitus using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change will be referred to a CDC (Center for Disease Control and Prevention) recognized diabetes prevention program (DPP), and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
Study NCT00651222 — intervention group
Intervention type: OTHER
Intervention: No intervention was required
Description: Death records were reviewed, therefore, there was no intervention
Study NCT04713930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: JNJ-61393215 will be administered orally.
Study NCT04713930 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study NCT05338138 — intervention group
Intervention type: DEVICE
Intervention: ultrasound guided central venous catheter insertion
Description: Prospective comparative randomized controlled clinical study.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Aortic/ cardiac magnetic resonance imaging
Description: MRI scans will be performed to detect systemic vascular involvement in GCA patients, aiming to provide detailed images of affected tissues.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vascular ultrasound
Description: Vascular ultrasound will be employed to examine the temporal and axillary arteries in GCA patients, searching for signs indicative of active inflammation.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transorbital Ultrasound
Description: Transorbital ultrasound will be employed to assess the ophthalmic artery and its branches in GCA patients to detect intracranial inflammatory processes that could lead to severe neuro-ophthalmological complications.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-Enhanced Ultrasound
Description: Contrast-Enhanced Ultrasound (CEUS) is utilized to evaluate aortic involvement in GCA patients as an alternative, bed-side, realtime, radiation-free diagnostic tool.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography angiography
Description: OCTA will be used to assess vascular changes in the retina of GCA patients, providing detailed imaging that can help detect early signs of ocular involvement and identify risk factors of anterior ischemic optic neuropathy.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fluorescein angiography
Description: Fluorescein angiography will be performed to evaluate blood circulation and highlight any blockages in the blood vessels of the retina in patients with GCA to detect vascular abnormalities that may lead to severe vision complications.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fundus autofluorescence
Description: This imaging technique will be used to observe the health of the retina and detect any changes in GCA patients that could suggest disease activity, particularly useful for assessing the integrity of the retinal pigment epithelium.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Color Fundus Photography
Description: Color fundus photography will be used to document the appearance of the optic disc and retinal vasculature in GCA patients, aiding in the long-term monitoring of ocular changes and the effects of therapeutic interventions.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cell-based ex-vivo assay with high-content analysis
Description: This assay predicts individual patient responses to different DMARDs by analyzing patient-derived PBMCs for specific immune responses to therapeutic agents.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 3'mRNA sequencing
Description: 3'mRNA sequencing analyzes gene expression profiles related to the immune response in PMR/GCA patients, aiding in understanding the genetic underpinnings of inflammation and vascular remodeling.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Enzyme-linked immunosorbent assay
Description: Used to measure cytokine levels in the serum and plasma of PMR/GCA patients, ELISA aids in profiling inflammatory markers that are indicative of disease activity and response to treatment.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometry
Description: Employed to analyze immune cell phenotypes in patients with PMR and/or GCA, this test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and guiding therapy.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory assessment:
Description: Serum Chemistry (nt-proBNP, troponin T, CRP, ESR, blood count)
Study NCT06400784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Isosorbide dinitrate (5mg bd) and Hydralazine (25mg bd) will be added on top of conventional heart failure medications.
Study NCT06400784 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isosorbide Dinitrate
Description: Isosorbide dinitrate (5mg bd) and Hydralazine (25mg bd) will be added on top of conventional heart failure medications.
Study NCT05466305 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Gold plated chrome cobalt alloy
Description: Acrylic resin complete denture having a metal chrome cobalt palatal plate which plated by gold
Study NCT05466305 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gold plated chrome cobalt alloy
Description: Acrylic resin complete denture having a metal chrome cobalt palatal plate which plated by gold
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Immunohistochemistry of Temporal Artery Biopsies
Description: Immunohistochemistry staining of TAB to assess local expression of endothelial adhesion molecules in acute inflammation.
Study NCT06460142 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Functional assessment questionnaires
Description: The following questionnaires will be applied: FACIT-Fatigue, SF-36, BAS, Birmingham Vasculitis Activity Score, Montreal Cognitive Assessment, Mini-Mental Status Examination. These questionnaires collectively provide a comprehensive evaluation of the functional status, quality of life, and mental health of patients with GCA and PMR.
Study NCT06441279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-articular injection with Platelet lysate (PL).
Description: 2 ml of Platelet lysate will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly
Study NCT06441279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-articular injection with Hyaluronic Acid.
Description: 2 ml of Hyaluronic Acid will be deposited into the superior joint space (SJS) in the affected joint at the entry point slowly.
Study NCT06639633 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Anatomy Training with Enlarged %100 3D Printed Carpal Model Group
Description: After completing the general terminology part of the anatomy education in the first year, the participants will be recruited without moving on to the hand section of the upper extremity. Participants will undergo a 2-hour extra-curricular training, 60 minutes theoretical and 60 minutes practical. The training period will consist of 60 minutes of practical and theoretical lectures to be the same as the time allocated in the normal curriculum of the region. A 60-minute theoretical lecture on the anatomy of the carpal bone supported by 2-dimensional anatomical pictures will be given to both groups at the same time. Then they will take the practical lesson with carpal bones printed with 100% magnification on a 3D printer for 60 minutes.